We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Puracyp and Promega Combine Cell Line and Assay Systems for Complete Solution for Drug Developers
Product News

Puracyp and Promega Combine Cell Line and Assay Systems for Complete Solution for Drug Developers

Puracyp and Promega Combine Cell Line and Assay Systems for Complete Solution for Drug Developers
Product News

Puracyp and Promega Combine Cell Line and Assay Systems for Complete Solution for Drug Developers


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Puracyp and Promega Combine Cell Line and Assay Systems for Complete Solution for Drug Developers"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Puracyp Inc. and Promega Corporation have teamed up to provide all-inclusive kits to assess nuclear receptor activation, P450 metabolism, and cellular toxicity during the drug development process. These whole cell assay systems will identify compounds capable of activating nuclear receptors and inducing P450 metabolism while monitoring for cellular toxicity.

The assay kits contain components that have been designed and tested to work together in comprehensive user protocols.

Puracyp is contributing their proprietary nuclear receptor expressing cell lines, including cells for measuring human PXR activation by potential therapeutic agents.

Promega is bringing its leading assay and detection technologies for bioluminescent reporters, cell viability, and P450-Glo substrate-based metabolism assays.

Puracyp and Promega have launched a product line that includes DPX2™ cells (human PXR), rPXR cells (rodent PXR), MkB3 cells (monkey PXR) and 1A2-DRE cells (human AhR).

These cell-based assay systems and those under development (human CAR), are amenable to multiplexing whereby the investigator can assess activation, metabolism, and toxicity in a single well of a 96-well or 384-well plate.

Currently, Puracyp's DPX2™ stable cell line is the gold standard for assessing PXR activation by NCEs, and is utilized by many leading drug developers to provide pivotal information for predicting human drug-drug interactions. These products are available through the Puracyp website.

"These kits will allow scientists to answer critical questions about nuclear receptor activation and oxidative drug metabolism", said Dr. Jerome Lasker, Director of Laboratory Operations for Puracyp.

Puracyp CEO Mark Dale added, "Nuclear receptor activation and metabolism can be determined in a highly cost-effective manner using Puracyp's kits." Thomas Livelli, Promega Vice President of Life Sciences Products and Services, commented, "We believe this new offering will be extremely helpful to scientists and provide high value cell-based systems for discovery and development."

Advertisement